IgM anti-MAG paraproteinaemic neuropathy: clinical features
Evidence-based neurology checklist on igm anti-mag paraproteinaemic neuropathy: clinical features: Demographics Anti MAG antibodies are present in 50% of IgM neuropathy About 70% of these have MGUS The mean onset age is just over 60 years: range is about 25-90 years It usually affects men with no…
Demographics
- Anti MAG antibodies are present in 50% of IgM neuropathy
- About 70% of these have MGUS
- The mean onset age is just over 60 years: range is about 25-90 years
- It usually affects men with no other associated diseases
- There is no M protein in about 6% of cases
- There may be associated anti SGPG and anti-ganglioside antibodies
Risk factors
Phenotypes
Typical clinical features
Differential diagnosis of IgM without anti MAG antibody
Nerve conduction studies (NCS)
Outcome
Acronyms
References
- Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol 2010; 12:71-83.
- Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 2018; 11:1756285617746640.
- So YT. Immune-mediated neuropathies. Continuum (Minneap Minn) 2012; 18:85-105.
- Svahn J, Petiot P, Antoine JC, et al; Francophone anti-MAG cohort Group. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. JNNP 2018; 89:499-505.
- Sakamoto Y, Shimizu T, Tobisawa S, Isozaki E. Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein. Neurol Sci 2017; 38:2165-2169.
- And 4 more. Subscribe to see the full list
